Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GHR-LRX · 1 trial · 1 indication
IGF-1 is a hormone that manages the effects of growth hormone (GH) in the body. Baseline of IGF-1 is defined as the average value of Screening and Day 1. A negative percent change from Baseline indicated improvement.
| Arm | Type | Description |
|---|---|---|
| GHR-LRX 120 mg | EXPERIMENTAL | Participants received GHR-LRX 120 mg subcutaneous (SC) injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3). |
| GHR-LRX 160 mg | EXPERIMENTAL | Participants received GHR-LRX 160 mg SC injection once every month for 73 weeks with a booster dose administered on Day 15 (Week 3). |
| Name | Type | Description |
|---|---|---|
| GHR-LRX | DRUG | GHR-LRX was administered by SC injection. |
Inclusion Criteria: 1. Males or females with a documented diagnosis of Acromegaly\* who are 18 to 75 years old (inclusive) at the time of informed consent. 2. Have had pituitary surgery (e.g. transsphenoidal) unless there was a contraindication to surgery and are either acromegaly medical treatment...
GHR-LRx is an investigational drug being studied for the treatment of acromegaly, a condition caused by excess growth hormone. It is designed to reduce growth hormone receptor activity, potentially lowering hormone levels and alleviating symptoms. The drug is currently in clinical development and has not been approved for use.
GHR-LRx targets the growth hormone receptor. By inhibiting this receptor, the drug aims to block the effects of excess growth hormone in patients with acromegaly. This mechanism is intended to help manage the hormonal imbalance characteristic of the condition.
GHR-LRx is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for acromegaly.
GHR-LRx is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is being evaluated for safety, tolerability, and efficacy in patients with acromegaly.
GHR-LRx has been studied in a Phase 2 clinical trial with the identifier NCT04522180. This completed trial assessed the safety, tolerability, and efficacy of the drug in 34 patients with acromegaly. The study was conducted across multiple countries, including the United States and several European nations.
Yes, GHR-LRx is also known as IONIS-GHR-LRx. The clinical trial NCT04522180 used the name IONIS-GHR-LRx in its title. Both names refer to the same investigational drug being developed by Ionis Pharmaceuticals for the treatment of acromegaly.